Acquired Resistance Forum Video #10: Online advocate and ROS1 patient "Craig In PA" Uthe leads a Q&A with speakers from videos #8 and #9 at the Acquired Resistance in Lung Cancer Patient Forum.

[powerpress]

Acquired Resistance Forum Video #9: Dr. Alice Shaw of Massachusetts General Hospital detailed for patients the so-called "next generation" ALK/ROS1 inhibitors, both those commercially available and those still in development.

Acquired Resistance Forum Video #4: The first three speakers at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West. 

[powerpress]

Acquired Resistance Forum Video #3: Dr. Lecia Sequist of Massachusetts General Hospital detailed why doctors started doing repeat biopsies for patients receiving targeted therapies and how they help patients and doctors determine next steps in treatment.

[powerpress]

Dr. Lecia Sequist of Massachusetts General Hospital, discusses the concept of multiplex next generation sequencing and how it could change molecular oncology.

[powerpress]

Dr. Lecia Sequist of Massachusetts General Hospital gives her view on more widespread availability of new mutation tests.

[powerpress]

Dr. Lecia Sequist of Massachusetts General Hospital describes the new targets she envisions as relevant for effective treatments in lung cancer over the next several years. 

[powerpress]

Dr. Lecia Sequist provides her thoughts on how molecular oncology can soon begin affecting treatment plans for a broader range of patients with lung cancer, including those with squamous NSCLC and other lung cancer histologies.

[powerpress]

Dr. Lecia Sequist describes the state of the art and her view of current best practices on molecular testing for advanced non-small cell lung cancer.

[powerpress]

I'm happy to bring you now the second part of the Santa Monica webinar, developed with the LUNGevity Foundation, on "Molecular Markers in Advanced NSCLC: Who to Test and What to Test For?", in which I was joined by Drs.